A new systematic review, edited by Prof. Marco Colizzi, collects and analyzes the results of 47 randomized controlled clinical trials (RCTs) evaluating the efficacy and tolerability of Palmitoylethanolamide (PEA) in various human clinical conditions.
The growing body of scientific evidence accumulated over the last ten years allows PEA to be considered not only in relation to specific disorders, but also from a transdiagnostic perspective.
The focus is on PEA’s biomodulatory mechanism on neuroinflammation, a key process underlying many neurological and systemic diseases.
Prof. Colizzi’s review provides a comprehensive and up-to-date overview of the PEA clinical and biological profile, highlighting how its high-bioavailability formulations—particularly ultra-micronized ones—can act on:
- multiple molecular targets
- target cells (immuno-inflammatory, neuronal and glial),
- a variety of symptoms, from neurological and somatic disorders to visceral and neuropsychiatric ones, both as monotherapy and in association with other treatments.
By modulating the neuroinflammatory processes common to numerous pathological conditions, Palmitoylethanolamide confirms itself as an endogenous biomodulator of great clinical interests, offering new perspectives for supporting the management of complex, multifactorial disorders.
This review, in summary, consolidates the role of Palmitoylethanolamide as a key molecule in neuroscience research, confirming Epitech Group’s commitment to advancing innovation and scientific knowledge for the benefit of health.
